A Phase 3 interventional study of Semaglutide and Semaglutide Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 39th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 65th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 72nd largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, and was the 108th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks.
In addition to taking the medicine, participants will have talks with study staff about:
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 200 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) of
For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1- 4:
Exclusion Criteria:
Participants without T2D at screening:
Participants with T2D at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 44 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), 25 mg (weeks 13 to 16) and 50 mg (weeks 17 to 44).
Drug: Semaglutide
Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.
Drug: Semaglutide Placebo
Participants will receive semaglutide tablets orally once daily for 44 weeks.
Participants will receive placebo matched to semaglutide.
Relative Change in Body Weight
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 5 Percent
Measured as count of participants
Time frame: At end of treatment (week 44)
Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 10 Percent
Measured as count of participants
Time frame: At end of treatment (week 44)
Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 15 Percent
Measured as count of participants
Time frame: At end of treatment (week 44)
Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 20 Percent
Measured as count of participants
Time frame: At end of treatment (week 44)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Physical Function Domain
IWQOL-Lite-CT is a 20-item obesity-specific PRO measure used to assess the impact of body weight changes on patient's physical and psychosocial functioning in three composite scores (Physical Function, Physical and Psychosocial) and a Total score.
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Total score
IWQOL-Lite-CT is a 20-item obesity-specific PRO measure used to assess the impact of body weight changes on patient's physical and psychosocial functioning in three composite scores (Physical Function, Physical and Psychosocial) and a Total score.
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Impact of Weight on Daily Activities Quesionnaire (IWDAQ) - Total Score
IWDAQ is a 18-item obesity-specific PRO measure developed to evaluate daily activity limitations associated with excess weight. It uses an adaptive questionnaire design where the participant chooses the three IWDAQ activities they would most like to improve with weight loss and rate the degree of limitations in each of the three activities at baseline. The same three activities are assessed for degree of limitations at follow-up to allow for tracking of activities relevant to each individual.
Time frame: From randomisation (week 0) to end-of-treatment (week 44)
Change in Body Mass Index (BMI)
Measured in kilogram per square meter (kg/m\^2)
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Waist Circumference
Measured in centimeter (cm)
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Systolic Blood Pressure
Measured in millimeter of mercury (mmHg)
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Diastolic Blood Pressure
Measured in mmHg
Time frame: From randomisation (week 0) to end of treatment (week 44)
Change in Glycated Haemoglobin (HbA1c)
Measured in percentage point (%-point)
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Fasting Plasma Glucose
Measured as milligrams per decilitre (mg/dL)
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Fasting Serum Insulin
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Total Cholesterol
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in High-density Lipoprotein (HDL) Cholesterol
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Low-density Lipoproteins (LDL) Cholesterol
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Very Low-density Lipoproteins (VLDL) Cholesterol
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Triglycerides
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in Free Fatty Acids
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in High Sensitivity C-reactive Protein (hsCRP)
Measured as ratio to baseline
Time frame: From baseline (week 0) to end of treatment (week 44)
Change in waist-height ratio (WtHR)
Time frame: From baseline (week 0) to end of treatment (week 44)
Number of Treatment Emergent Adverse Events(TEAE's)
Measured as count of events
Time frame: From baseline (week 0) to end of treatment (week 44)
Number of Treatment Emergent Serious Adverse Events(TESAE's)
Measured as count of events
Time frame: From baseline (week 0) to end of study (week 51)
AUC 0-24h,sema,50mg,ss: Area Under The Semaglutide-Time Curve (0-24h) During a Dosing Interval at Steady State
Measured as hours\*nanomoles per litre (h\*nmol/L)
Time frame: Week 20
Cmax,sema,50mg,ss: Maximum Concentration at Steady State of Semaglutide 50 mg
Measured as nanomoles per litre (nmol/L)
Time frame: Week 20
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Jan 2025, 19 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide